Compare Strategy Inc. (MSTR) vs Oscar Health Inc (OSCR) Price & Performance

MSTR trades at $100.01, up 3.26% today, with a bullish technical signal despite recent earnings misses. The company reported Q2 2026 EPS of -$24.45 versus -$2.19 expected, continuing a trend of negative profitability. Analyst consensus remains positive with a $210 price target, though fundamentals show significant challenges including a negative net income margin of -6,102.96% and substantial Bitcoin-related investment outflows.

The outlook is mixed: strong analyst support suggests upside potential, but fundamental weaknesses and persistent earnings misses pose substantial risks. Investment opportunity exists if the company can leverage its cash position for growth, while risks include continued operational losses and dependence on Bitcoin market performance.

OSCR trades at $27.90, up 5.12% with strong recent earnings performance including Q2 2026 EPS beating estimates. The stock shows bearish technical signals but positive fundamental momentum with revenue growth from $11.7B to $15.3B and a swing to profitability. Recent news highlights record 2026 profitability and raised full-year guidance.

The outlook appears constructive with analyst consensus target of $32.50 offering 16% upside. Key risks include execution on growth targets and competitive pressures. The valuation remains attractive with P/S of 0.53, though investors should monitor Q3 earnings delivery against expectations.